PIOGLITAZONE AN Tablets 15 mg pioglitazone (as hydrochloride) 15 mg tablet blister pack

Страна: Австралия

Език: английски

Източник: Department of Health (Therapeutic Goods Administration)

Активна съставка:

Pioglitazone hydrochloride

Предлага се от:

Amneal Pharma Australia Pty Ltd

INN (Международно Name):

Pioglitazone hydrochloride

Листовка

_Pioglitazone AN tablets – Consumer Medicine Information _
_ _
_Doc ID: 88.AN.M.2.0 _
_ _
_ _
_Page 1 _
PIOGLITAZONE AN TABLETS
_Pioglitazone Hydrochloride _
CONSUMER MEDICINE INFORMATION
WHAT IS IN THIS LEAFLET
This
leaflet
answers
some
common
questions
about
PIOGLITAZONE AN.
It
does
not
contain
all
of
the
available information. It does not
take the place of talking to your
doctor or pharmacist.
All medicines have benefits and
risks. Your doctor has weighed
the
risks
of
you
taking
PIOGLITAZONE AN against the
benefits they expect it will have
for you.
IF
YOU
HAVE
ANY
CONCERNS
ABOUT
TAKING
THIS
MEDICINE,
TALK
TO
YOUR
DOCTOR
OR
PHARMACIST.
Keep
this
leaflet
with
your
medicine.
You may need to read it again.
WHAT PIOGLITAZONE
AN IS USED FOR
PIOGLITAZONE AN is a tablet
that
is
used
to
improve
the
action
of
the
body's
naturally
produced
insulin.
PIOGLITAZONE AN is used in
the
management
of
type
2
diabetes not controlled by diet.
PIOGLITAZONE
AN
helps
to
control the level of glucose in
your blood when you have type
2
diabetes.
This
is
the
'adult
onset' type of diabetes and is
controlled
by
diet,
certain
oral
medications
and
occasionally
insulin.
This
medicine
is
also
called
pioglitazone
hydrochloride
and
belongs to a group of medicines
called
glitazones.
Glitazones
decrease insulin resistance.
ASK YOUR DOCTOR IF YOU HAVE
ANY QUESTIONS ABOUT WHY THIS
MEDICINE HAS BEEN PRESCRIBED
FOR YOU.
Your
doctor
may
have
prescribed it for another reason.
PIOGLITAZONE
AN
can
be
used
alone
(when
diet
and
exercise is not enough to treat
your diabetes) or together with
other anti-diabetic medicines.
This medicine is available only
with a doctor's prescription.
The use of PIOGLITAZONE AN
has not been studied in children
.
BEFORE YOU TAKE
PIOGLITAZONE AN
_WHEN YOU MUST NOT TAKE _
_PIOGLITAZONE AN _
DO
NOT
TAKE
PIOGLITAZONE
AN IF:
•
YOU
HAVE
HEART
FAILURE
REQUIRING
TREATMENT.
TALK
TO YOUR DOCTOR IF YOU HAVE
HEART FAILURE
•
YOU HAVE TYPE 1 DIABETES
OR
DIABETIC
KETOACIDOSIS
(OFTEN CAUSED B VERY HIGH
BLOOD GLUCOSE LEVELS)
•
YOU HAVE H

Данни за продукта

_Pioglitazone AN tablets Product Information _
_ _
_ _
_ _
_ Amneal Pharma Australia Pty Ltd _
Pioglitazone AN.PI v5.0
Page 1
PIOGLITAZONE AN
_ _
_(PIOGLITAZONE TABLETS) _
_ _
PRODUCT INFORMATION
_ _
NAME OF THE MEDICINE
The active ingredient in PIOGLITAZONE AN tablets is pioglitazone
hydrochloride.
CHEMICAL NAME:
(±)-5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione
hydrochloride
MOLECULAR FORMULA:
C
19
H
20
N
2
O
3
S. HCl
MOLECULAR WEIGHT:
392.90
CAS REGISTRY NUMBER: _[112529-15-4]_
DESCRIPTION
Pioglitazone is off-white to pale yellow colour powder. It is soluble
in methanol, practically
insoluble in water.
PIOGLITAZONE AN is available as tablets containing 15, 30 & 45 mg
pioglitazone as
hydrochloride.
PIOGLITAZONE AN tablets contain the following inactive ingredients:
Lactose monohydrate,
carmellose
calcium, hyprolose and magnesium stearate.
PHARMACOLOGY
Pioglitazone is an oral antidiabetic agent that acts primarily by
decreasing insulin resistance.
Pharmacological studies indicate that pioglitazone improves
sensitivity to insulin in muscle and
adipose tissue and inhibits hepatic gluconeogenesis. Pioglitazone
improves glycaemic control
while reducing circulating insulin levels.
Fasting and postprandial glycaemic control are improved in patients
with type 2 diabetes mellitus.
The
decreased
insulin
resistance
produced
by
pioglitazone
results
in
lower
blood
glucose
concentrations, lower plasma insulin levels and lower HbA
1c
values.
_Pioglitazone AN tablets Product Information _
_ _
_ _
_ _
_ Amneal Pharma Australia Pty Ltd _
Pioglitazone AN.PI v5.0
Page 2
MODE OF ACTION
Pioglitazone is a thiazolidinedione antidiabetic agent that depends on
the presence of insulin for
its unique mechanism of action. Pioglitazone decreases insulin
resistance in the periphery and in
the liver resulting in increased insulin-dependent glucose disposal
and decreased hepatic glucose
output. Unlike sulfonylureas, pioglitazone is not an insulin
secretagogue. Pioglitazone is a potent
and highly selective agonist f